STOCK TITAN
  1. Home
  2. News
  3. SPRO

Spero Therapeutics, Inc. - $SPRO STOCK NEWS

Welcome to our dedicated page for Spero Therapeutics news (Ticker: $SPRO), a resource for investors and traders seeking the latest updates and insights on Spero Therapeutics stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Spero Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Spero Therapeutics's position in the market.

News
Spero Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on Wednesday, May 15, 2024
Rhea-AI Summary

Spero Therapeutics, Inc. (Nasdaq: SPRO) will report its first quarter 2024 financial results and business update on May 15, 2024. The company focuses on developing treatments for rare diseases and MDR bacterial infections.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
-
News
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary

Spero Therapeutics, Inc. announced the approval of 10,833 restricted stock unit awards to a new employee under the 2019 Inducement Plan. The RSUs will vest in four equal annual installments beginning on May 1, 2025, subject to the employee's continued employment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.21%
Tags
none
-
News
Spero Therapeutics Announces Fourth Quarter and Full Year 2023 Operating Results and Provides a Business Update
Rhea-AI Summary
Spero Therapeutics, Inc. (SPRO) announces financial results for Q4 and full year 2023, along with updates on SPR720 Phase 2a trial, Tebipenem HBr Phase 3 trial, and IND submission for SPR206. The company reiterates expected cash runway into late 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.82%
Tags
earnings
News
Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 13, 2024
Rhea-AI Summary
Spero Therapeutics, Inc. (SPRO) will host a conference call to report Q4 and full year financial results, updating on its business and pipeline. The call is on March 13, 2024, at 4:30 p.m. ET. SPRO focuses on rare diseases and MDR bacterial infections.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.99%
Tags
earnings
-
News
Spero Therapeutics Announces Clearance of IND for SPR206 to Treat MDR Gram-negative Bacterial Infections
Rhea-AI Summary
Spero Therapeutics, Inc. (SPRO) receives FDA clearance for Phase 2 study of SPR206, a novel antibiotic for HABP/VABP caused by MDR Gram-negative bacterial infections. The drug aims to address unmet medical needs in treating serious infections. The study will evaluate safety, efficacy, and pharmacokinetics in combination with select antibiotics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.22%
Tags
none
-
News
Spero Therapeutics to Present at Cowen’s 44th Annual Healthcare Conference
Rhea-AI Summary
Spero Therapeutics, Inc. (SPRO) announced that its President and CEO will present at the Cowen 44th Annual Healthcare Conference. The company focuses on developing therapies for rare diseases and MDR bacterial infections. The presentation is scheduled for March 4, 2024, with webcast details provided.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.66%
Tags
conferences
News
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Spero Therapeutics, Inc. (Nasdaq: SPRO) has announced the approval of 50,000 restricted stock unit awards (RSUs) for a new employee under the 2019 Inducement Equity Incentive Plan. The RSUs will vest in four equal annual installments beginning on February 1, 2025, subject to the employee's continued employment with Spero on such vesting dates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.29%
Tags
none
-
News
Spero Therapeutics Provides Corporate Update and 2024 Outlook
Rhea-AI Summary
Spero Therapeutics Inc. (SPRO) provided a corporate update highlighting its recent accomplishments and anticipated milestones for 2024. The company expects to provide Phase 2a topline proof-of-concept data from its lead program SPR720 in NTM-PD patients in 2H 2024. It has initiated dosing in the PIVOT-PO Phase 3 trial for tebipenem HBr in cUTI patients, with a target enrollment of approximately 2,648 patients, expected to be completed in 2H of 2025. Spero is entitled to receive $95 million in development milestones, payable over two years, as part of the GSK license agreement. The company's preliminary cash balance as of December 31, 2023, was approximately $76.3 million, with a cash runway guidance into late 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.72%
Tags
none
-
News
Spero Therapeutics Announces First Patient, First Visit for Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr in Complicated Urinary Tract Infections
Rhea-AI Summary
Spero Therapeutics, Inc. (Nasdaq: SPRO) announced the first patient, first visit for PIVOT-PO, a global pivotal Phase 3 clinical trial of tebipenem HBr in patients with complicated urinary tract infections (cUTI), including acute pyelonephritis (AP). Spero is entitled to receive $95 million in development milestone payments from GSK, payable in four equal installments over two years. The trial is designed to enroll approximately 2,648 patients, with randomization stratified by age, baseline diagnosis, and the presence or absence of urinary tract instrumentation. Positive results from PIVOT-PO could support approval of tebipenem HBr as a treatment for cUTI, including pyelonephritis, for a limited use indication.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.4%
Tags
clinical trial
News
Spero Therapeutics Announces Third Quarter 2023 Operating Results and Provides a Business Update
Rhea-AI Summary
Spero Therapeutics, Inc. (Nasdaq: SPRO) has announced a Special Protocol Assessment Agreement with FDA for Phase 3 PIVOT-PO trial of tebipenem HBr. The trial is expected to begin with First Patient, First Visit in 4Q 2023. The company also provided a business update and third-quarter financial results, highlighting substantial progress across its late-stage programs throughout 2023 and anticipated milestones before year-end.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.8%
Tags
earnings
Stock SPRO logo
Spero Therapeutics, Inc.

Nasdaq:SPRO

SPRO Rankings

#4384 Ranked by Market Cap
#4611 Ranked by Stock Gains
N/A Ranked by Dividends

SPRO Stock Data

89.46M
37.43M
20.38%
26.12%
1.21%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
CAMBRIDGE

About SPRO

spero therapeutics is focused on the development of novel therapies to treat highly resistant bacterial infections. the culture at spero is one of respect, action, collaboration and transparency. spero team members are leaders in the field, and have the ability and desire to be a part of a team. at spero, a feeling that we are part of something groundbreaking and innovative fuels our approach.